Veracyte’s pioneering genomic tests are setting new standards in thyroid cancer, lung cancer and idiopathic pulmonary fibrosis (IPF) diagnosis, where we are helping to provide better diagnostic answers and reduce the need for invasive surgeries. To date, we have received over 325,000 patient samples, performed over 100,000 genomic tests, saved more than an estimated 40,000 patients from unnecessary surgery and provided more than $800 million in estimated cost savings to the healthcare system.
  • Afirma
    Reducing unnecessary surgeries in thyroid cancer diagnosis
    Learn more  >
  • Percepta
    Reducing unnecessary invasive procedures in lung cancer diagnosis
    Learn more  >
  • Envisia
    Increasing confidence in idiopathic pulmonary fibrosis diagnosis
    Learn more  >